Literature DB >> 19173372

Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors.

Marco Mula1, Michael R Trimble.   

Abstract

Cognitive dysfunction is frequently observed in patients with epilepsy and represents an important challenge in the management of patients with this disorder. In this respect, the relative contribution of antiepileptic drugs (AEDs) is of relevance. The fact that a considerable number of patients require AED therapy for many years, or perhaps even a lifetime, emphasizes the need to focus on the long-term adverse effects of these drugs on cognition. The most prevalent of the CNS adverse effects observed during AED therapy are sedation, somnolence, distractibility, insomnia and dizziness. Sedation, in particular, is associated with most of the commonly used AED therapies. Nevertheless, cognitive function in individuals with epilepsy may also be influenced by several factors, of which AEDs constitute only one of many putative causes. In general terms, most studies agree that some differences exist among the older AEDs with regard to the effects on cognition, and some newer generation molecules may have a better cognitive profile than older AEDs. The mechanisms of action are an obvious determinant; however, there is still a lack of evidence for differentiation between available drugs with regard to cognitive effects. Some authors have suggested that there may be different cognitive effects associated with individual drugs; however, the question as to whether there are more specific deficits related to the action of individual drugs remains unsolved. There seems to be agreement that polytherapy and high-dose treatment can produce cognitive adverse effects and when high dosages or adjunctive polytherapy is needed, the balance between benefits and disadvantages may be negatively biased against drug treatment. Thus, drug treatment requires careful balancing in the attempt to reach maximal seizure control while avoiding neurotoxic adverse effects. Finally, the mood status of the patient and clinical relevance of the information obtained by neuropsychological testing represent important variables that need to be taken into account when discussing cognitive adverse effects of AEDs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19173372     DOI: 10.2165/00023210-200923020-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  99 in total

Review 1.  Cognitive function--victim of disease or hostage to treatment?

Authors:  F E Dreifuss
Journal:  Epilepsia       Date:  1992       Impact factor: 5.864

2.  Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy.

Authors:  A M McGuire; J S Duncan; M R Trimble
Journal:  Epilepsia       Date:  1992 Jan-Feb       Impact factor: 5.864

Review 3.  Issues associated with repeated neuropsychological assessments.

Authors:  R J McCaffrey; H J Westervelt
Journal:  Neuropsychol Rev       Date:  1995-09       Impact factor: 7.444

4.  Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy.

Authors:  D Blum; K Meador; V Biton; T Fakhoury; B Shneker; S Chung; K Mills; A Hammer; J Isojärvi
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

5.  Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy.

Authors:  C B Dodrill; J L Arnett; K W Sommerville; N M Sussman
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

6.  The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate.

Authors:  Bettina Gomer; Kathrin Wagner; Lars Frings; Josef Saar; Astrid Carius; Markus Härle; Bernhard J Steinhoff; Andreas Schulze-Bonhage
Journal:  Epilepsy Behav       Date:  2007-04-03       Impact factor: 2.937

7.  Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy.

Authors:  N Fritz; S Glogau; J Hoffmann; M Rademacher; C E Elger; C Helmstaedter
Journal:  Epilepsy Behav       Date:  2005-05       Impact factor: 2.937

Review 8.  Behaviour, cognition and epilepsy.

Authors:  A P Aldenkamp; N Bodde
Journal:  Acta Neurol Scand Suppl       Date:  2005

9.  Carbamazepine (CBZ) controlled release compared with conventional CBZ: a controlled study of attention and vigilance in children with epilepsy.

Authors:  M S Pieters; A Jennekens-Schinkel; T Stijnen; P M Edelbroek; O F Brouwer; L Liauw; A Heyer; J B Lanser; A C Peters
Journal:  Epilepsia       Date:  1992 Nov-Dec       Impact factor: 5.864

10.  The Neurotoxicity Scale: the validity of a patient-based scale, assessing neurotoxicity.

Authors:  A P Aldenkamp; G Baker; M S Pieters; H C Schoemaker; A F Cohen; S Schwabe
Journal:  Epilepsy Res       Date:  1995-03       Impact factor: 3.045

View more
  31 in total

Review 1.  Seizures in oligodendroglial tumors.

Authors:  Melissa Kerkhof; Christa Benit; Alberto Duran-Pena; Charles J Vecht
Journal:  CNS Oncol       Date:  2015-10-19

2.  Antiepileptic drugs and suicide: the light at the end of the tunnel.

Authors:  Rochelle Caplan
Journal:  Epilepsy Curr       Date:  2014-05       Impact factor: 7.500

3.  Long-term outcome of patients with disorders of consciousness with and without epileptiform activity and seizures: a prospective single centre cohort study.

Authors:  Angelo Pascarella; Luigi Trojano; Vincenzo Loreto; Leonilda Bilo; Pasquale Moretta; Anna Estraneo
Journal:  J Neurol       Date:  2016-07-14       Impact factor: 4.849

4.  Differences in paracingulate connectivity associated with epileptiform discharges and uncontrolled seizures in genetic generalized epilepsy.

Authors:  Benjamin P Kay; Scott K Holland; Michael D Privitera; Jerzy P Szaflarski
Journal:  Epilepsia       Date:  2014-01-21       Impact factor: 5.864

5.  Name as Many AEDs as You Can in One Minute: Antiepileptic Drugs and the Disruption of Verbal Fluency Networks.

Authors:  Bernard S Chang
Journal:  Epilepsy Curr       Date:  2018 Mar-Apr       Impact factor: 7.500

6.  Cognitive Burden of Common Non-antiretroviral Medications in HIV-Infected Women.

Authors:  Leah H Rubin; Kendra K Radtke; Seenae Eum; Bani Tamraz; Krithika N Kumanan; Gayle Springer; Pauline M Maki; Kathryn Anastos; Daniel Merenstein; Roksana Karim; Kathleen M Weber; Deborah Gustafson; Ruth M Greenblatt; Jeffrey R Bishop
Journal:  J Acquir Immune Defic Syndr       Date:  2018-09-01       Impact factor: 3.731

Review 7.  Neurocognitive function after radiotherapy for paediatric brain tumours.

Authors:  Laetitia Padovani; Nicolas André; Louis S Constine; Xavier Muracciole
Journal:  Nat Rev Neurol       Date:  2012-09-11       Impact factor: 42.937

Review 8.  Topiramate and cognitive impairment: evidence and clinical implications.

Authors:  Marco Mula
Journal:  Ther Adv Drug Saf       Date:  2012-12

9.  Phenobarbital use and neurological problems in FMR1 premutation carriers.

Authors:  Wilmar Saldarriaga; Pamela Lein; Laura Yuriko González Teshima; Carolina Isaza; Lina Rosa; Andrew Polyak; Randi Hagerman; Santhosh Girirajan; Marisol Silva; Flora Tassone
Journal:  Neurotoxicology       Date:  2016-01-21       Impact factor: 4.294

10.  Neurocognitive dysfunction in adult moyamoya disease.

Authors:  Joanne R Festa; Lauren R Schwarz; Neil Pliskin; C Munro Cullum; Laura Lacritz; Fady T Charbel; Dana Mathews; Robert M Starke; E Sander Connolly; Randolph S Marshall; Ronald M Lazar
Journal:  J Neurol       Date:  2009-12-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.